NCT04438083TERMINATEDanonymous

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation

Sponsor

Source record

CRISPR Therapeutics AG

Phase

Source record

Phase 1

Modality

AI-normalized

gene therapy

Target

AI-normalized

CD70-directed T-cell immunotherapy using CRISPR-Cas9 gene editing technology.

Indication / condition

AI-normalized

Renal Cell Carcinoma

Intervention

Source record

CTX130

Source & freshness

Source record

NCT ID

NCT04438083

Original source

ClinicalTrials.gov

Source last updated

Jan 08, 2025

Ingested at

Jun 16, 2026

Internal sync

Jun 16, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04438083

Title

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation

Sponsor

CRISPR Therapeutics AG

Status

TERMINATED

Phase

Phase 1

Condition raw

Renal Cell Carcinoma

Condition normalized

Renal Cell Carcinoma

Modality raw

gene therapy

Modality normalized

gene therapy

Target raw

CD70-directed T-cell immunotherapy using CRISPR-Cas9 gene editing technology.

Target normalized

CD70-directed T-cell immunotherapy using CRISPR-Cas9 gene editing technology.

Interventions

CTX130

Public preview

Source record

CRISPR Therapeutics AG is advancing CTX130, an allogeneic CAR T-cell therapy targeting CD70, in patients with advanced renal cell carcinoma (RCC). The market for RCC therapies is competitive, with several established and emerging treatments. CTX130's unique mechanism of action may provide a differentiated therapeutic option, particularly for patients who have exhausted standard treatments. However, the termination of the trial suggests potential challenges in achieving desired efficacy or safety endpoints, necessitating careful evaluation of future development strategies and market positioning.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT04438083

Status

TERMINATED

Phase

Phase 1

Sponsor

CRISPR Therapeutics AG

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJan 08, 2025

Internal syncJun 16, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04438083

Indication

Renal Cell Carcinoma

Modality

gene therapy

Target

CD70-directed T-cell immunotherapy using CRISPR-Cas9 gene editing technology.

Intervention

CTX130

Source record